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Abstract
Adenosine is a neuromodulator that regulates the body’s response to dopamine 
and another neurotransmitter in the brain that is responsible for motoric, emotion, 
learning, and memory function. Adenosine is a G-protein-coupled receptor and 
has four subtypes, which are A1, A2A, A2B, and A3. Adenosine A2A is located in the 
striatum of the brain. Antagonist interferes with GABA releasing, modulates acetyl-
choline and releases dopamine, and also facilitates dopamine receptor’s signaling. 
Therefore, it can reduce motoric symptoms in Parkinson’s disease. Adenosine A2A 
antagonist is also believed to have neuroprotective effects. Several compounds have 
been reported and have undergone clinical test as selective adenosine A2A antago-
nists, including istradefylline, preladenant, tozadenant, vipadenant, ST-1535, and 
SYN-115. Nonselective adenosine A2A antagonists from natural compounds are 
caffeine and theophylline.
Keywords: adenosine A2A, selective adenosine A2A antagonists, Parkinson’s disease, 
neuroprotective, natural compounds
1. Introduction
Adenosine is a neuromodulator that coordinates responses to dopamine and 
other neurotransmitters in areas of the brain responsible for motor function, mood, 
learning, and memory [1]. Adenosine consists of four receptor subtypes: A1, A2A, 
A2B, and A3 belonging to the superfamily of G-protein-coupled receptor. Adenosine 
A1 and A3 receptors are coupled to inhibitory G proteins, while A2A and A2B recep-
tors are coupled to stimulatory G proteins [2].
Adenosine A1 receptor can be found in adipose tissue, heart muscle, and inflam-
matory cells. The receptor mostly expressed by the central nervous system such 
as neocortex, cerebellum, hippocampus, and dorsal horn of the spinal cord [3]. 
The pre- and postsynaptic nerve terminals, mast cells, airway smooth muscle, and 
circulating leukocytes are the places where adenosine A2 receptor can be found. As 
the more widely dispersed receptor, adenosine A2 is divided into two receptors on 
the basis of high- and low-affinity for adenosine, A2A and A2B [4]. Striatal neurons 
are where the adenosine A2A are highly enriched; however its lower levels can also be 
found in glial cells and neurons outside the striatum [5]. The adenosine A2B recep-
tors are highly expressed in the gastrointestinal tract, bladder, lung, and on mast 
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Figure 1. 
Basal ganglia circuitry in normal conditions.
cells. The most widely dispersed receptor is the A3 receptor which can be found in 
the kidney, testis, lung, mast cells, eosinophils, neutrophils, heart, and the brain 
cortex [4].
Adenosine A2A receptors are found to be concentrates in GABAergic medium-
sized spiny neurons in the dopamine-rich regions of the brain. The protein trans-
lated in the adenosine A2A is carried by many other tissues such as blood vessels, 
endothelial, lymphoid cells, smooth muscle cells, and several neurons in sympa-
thetic and parasympathetic systems [6]. Therefore, the dispersion of adenosine 
A2A is not limited to the medium spiny neurons in the basal ganglia. It stimulates 
the modulation of cAMP production and increases the level of adenylyl cyclase. 
This receptor is essential in giving the medium of vasodilation of coronary arteries 
which then supports the combination of new blood vessels and giving protection 
for tissues from indirect inflammatory damage [7]. The role of the A2A in the brain 
includes influencing the activity within the indirect pathway of the basal ganglia. 
The A2A has complicated actions because it colocalizes and is physically combined 
with other unrelated G-protein-coupled receptors. Therefore, it can form heterodi-
mers such as dopamine D2/A2A, and D3/A2A, cannabinoid CB1/A2A, and glutamate 
mGluR5/A2A, as well as CB1/A2A/D2 heterotrimers [7].
The pathways which give signals used by the A2A receptor depend on the location 
of the cell and tissue, the specific G protein which couples it, and the signaling in 
the cell. The brain also carries the A2A receptor in which it plays an important role 
in regulating the glutamate and releasing the dopamine [8]. In the striatopallidal 
neurons, dopamine D2 receptors are colocalized with adenosine A2A receptors. 
Adenosine A2A receptor activity that mediates stimulation and D2 receptors that 
mediate inhibition in the striatopallidal pathway are balanced [9]. The adenosine A2A 
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likely affects motor activity by acting at different levels of the basal ganglia network. 
The basal ganglia comprise the striatum (putamen), the globus pallidus externa 
(GPe), the globus pallidus interna (GPi), substantia nigra pars compacta (SNc), 
substantia nigra reticulata (SNr), and the subthalamic nucleus (STN). The striatum 
is represented by medium-sized spiny projection neurons (MSNs), accounting 
for almost 95% of striatal neurons and using γ-aminobutyric acid (GABA) as 
neurotransmitter. The GABAergic spiny neurons give rise to the two main striatal 
efferent circuits: the striatonigral and the striatopallidal pathway. The neurons of the 
striatonigral (direct) pathway contain the neuropeptide substance P and dynorphin 
and mainly express D1 receptors; this pathway directly projects from the striatum 
to the GPi/SNr. The neurons of the striatopallidal (indirect) pathway containing the 
neuropeptide, enkephalin (ENK), predominantly express D2 receptors; this circuit 
connects the striatum with the GPi/SNr via synaptic connections in the GPe and 
STN in Figure 1. Dopamine modulates motor coordination and fine movements 
by facilitating the action of the direct pathway on stimulatory D1 receptors and by 
inhibiting indirect pathway function acting on inhibitory D2 receptors [10].
The adenosine A2A receptor has agonists and antagonists of which the roles are 
potentiating and inhibiting, respectively. The D2 receptor agonist has effects on 
motor activity, the releasing of neurotransmitter, and the expression of striatal of 
c-Fos, a factor of transcription which is used as neuronal activity’s indirect marker 
[11]. The adenosine A2A receptor has a key role in regulating the striatal dopaminer-
gic neurotransmission which produces substances that are valuable to treat neuro-
logical disorders that are relevant with dopaminergic dysfunction.
The topology of G-protein-coupled receptor is displayed in the structure of the 
adenosine A2A receptor. These receptors have a central core which consists of seven 
Figure 2. 
Crystal structure of the adenosine A2A receptor (4EIY) shown in the membrane structure. The extracellular 
and intracellular parts of the membrane are shown in red and blue beads, respectively. The disorder residues of 
intracellular loop (IL2) are modeled in dashed line.
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transmembrane helices (7TM). Each of the TM is mainly α-helical and consists of 
20–27 amino acids. Three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops connect each of the TM domain. A short helix TM8 runs 
parallel to the cytoplasmic surface of the membrane. The adenosine A2A recep-
tor has differences in length and N-terminal extracellular domain function, their 
domain of C-terminal intracellular, and their loops of intracellular/extracellular. 
These differences are shown in Figure 2.
2. The role of adenosine A2A in Parkinson’s disease
Parkinson’s disease (PD) is a chronic neurodegenerative disorder in the brain, 
marked by motoric symptoms [12]. The motoric symptoms in PD are resting 
tremor, rigidity, bradykinesia, and postural disorder. Besides motoric symptoms, 
PD also has non-motoric symptoms such as depression, hallucination, sleeping 
disorder, and decreasing cognitive and sensory functions. The main pathological 
characteristic of PD is the loss of dopaminergic neurons in substantia nigra pars 
compacta, a region in the brain that controls all the body movement and forms the 
dopamine. The development of PD also includes the formation of Lewy body, a 
deposit of cytoplasmic, eosinophilic neuronal inclusions, composed of the presyn-
aptic protein α-synuclein [13, 14].
The current therapy of PD is targeted at dopamine replacement, thereby 
decreasing the motor symptoms. It includes precursor of dopamine (levodopa), 
dopamine agonists [15, 16] monoamine oxidase type B (MAO-B) inhibitors [17], 
and catechol-O-methyltransferase (COMT) inhibitors [17, 18]. These agents 
produce undesirable side effects such as on-off effects, hallucinations, and dyskine-
sia. These effects get more severe as the treatment continued. The efficacy of these 
agents is also decreasing as the disease progressed [19].
Because of the undesirable side effects of dopamine replacement therapy, the 
non-dopaminergic therapy is continuously being explored. One of the approaches 
is selective adenosine A2A antagonist [20, 21]. Adenosine A2A receptors are found 
mainly in the striatum of rat [22, 23], which has similar distribution with the 
human brain [24, 25]. In the striatum, adenosine A2A receptors are colocalized 
with dopamine D2 receptors. These two receptors have opposite effect on motoric 
function [26]. The activation of adenosine A2A receptors will inhibit the signaling of 
dopamine D2 receptors, and conversely, the inhibition of signaling of adenosine A2A 
receptors will increase the activation of dopamine D2 receptors, therefore facilitat-
ing dopamine D2-mediated responses [11]. The inhibition of adenosine A2A recep-
tors showed motoric improvement in animal models of PD [27–30]. This also has 
desirable effect on long-term levodopa treatment such as decreasing the dyskinesia 
and increasing the therapeutic effect on levodopa [31, 32].
3. Adenosine A2A receptor antagonist as a neuroprotective
For years, adenosine-dopamine interactions have been investigated in order to 
observe their relevance for treatment of central nervous system (CNS) disorders 
[33]. It is assumed that adenosine A1 receptors (A1Rs) play an important role in 
neuroprotection as their activation at the onset of neuronal injury has shown to 
reduce brain damage in adult animal model. Vice versa, their blockade aggravates 
the damage. In other hand, adenosine A2 receptors (A2ARs) are shown to be 
upregulated in harmful brain conditions, and their blockade shows brain neuro-
protection in studied animals [34]. The blockade of A2ARs alleviates the long-term 
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burden of brain disorders in different neurodegenerative conditions, namely, 
ischemia, epilepsy, and Parkinson’s and Alzheimer’s disease, through its control 
on neuronal cell death [35].
A2ARs have been shown to be viable in serving as alternative non-dopaminergic 
strategy of Parkinson’s disease treatment because of their limited distribution in the 
striatum and the intense interaction between adenosine and dopamine receptors 
in the brain. A2ARs antagonists were shown to improve motor function in different 
animal models (primates and rodents), alone or co-administered with dopamino-
mimetic drugs, levodopa, or dopamine agonists [35]. Based on rigorous preclinical 
animal studies, istradefylline (KW6002) has shown its promising ability to increase 
motor activity in PD of the advanced stage in clinical phase IIB trial [36]. It became 
the first therapeutic agent developed to target A2ARs, and other similar compounds 
will be available in near future [37].
The recent meta-analysis (n = 6) suggested that 20 mg of istradefylline improves 
unified Parkinson’s disease ranking scale (UPDRS) III. Meanwhile at 40 mg per 
day, istradefylline could alleviate off time and motor symptoms derived from 
Parkinson’s disease [38]. Phase 3 study (613 randomized patients), done by Isaacson 
et al. concluded that greater reduction from baseline in total hours off time/day 
were shown at all-time points for istradefylline 20 and 40 mg/day, compared to 
placebo. However, future development is needed as the study has not yet reached 
statistical significance [39].
In the case of Parkinson’s disease, microglia has been suggested to be the most 
likely cell type to be targeted by A2ARs antagonists [40]. In vitro and in vivo studies 
showed that local neuroinflammation make glial cells (especially microglial cells) 
particularly sensitive to A2AR modulation [41]. Previous research done by Gao 
and Phillis is the first study to demonstrate nonselective A2AR antagonist action in 
reducing cerebral ischemic injury in the gerbil, following global forebrain ischemia 
[42]. After that, many studies have reported the neuroprotective of A2AR antago-
nists in different models of ischemia [43].
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that is indi-
cated by the progressive loss of memory and other cognitive functions, leading to 
dementia [44, 45]. Adenosine can control and integrate cognition and memory 
[46]. Both A1Rs and A2ARs, mainly located in synapses, control the release of 
neurotransmitters which are involved in memory or other cognitive processes  
[34, 47]. Methylxanthine was discovered to act as nonselective adenosine receptors 
antagonist. Caffeine, the most famous methylxanthine found in common bever-
ages, is the most widely consumed psychoactive drug. Maia and de Mendonca pre-
sented the first epidemiological data showing that the incidence of AD is inversely 
proportioned with coffee consumption [48]. Several other studies also show this 
inverse relationship [49–51]. Animal models also shown that caffeine intake may be 
beneficial for AD. In a study, a 6-month period of 0.3 g/L caffeine intake alleviated 
the cognitive deficits found in AD transgenic mice (APPsw). Furthermore, these 
mice culture neurons showed the reduced production of Aβ1–40 and Aβ1–42 peptides 
[52]. A2ARs antagonists and/or caffeine prophylactic and long-term neuroprotective 
process are suggested to be based on inhibition of reactive oxygen species activity, 
tau pathology, and Aβ production by neuronal cells [53].
A2ARs antagonist may also serve as antidepressants, as observed in animal model 
of antidepressants screening test done by El-Yacoubi et al. [54, 55]. In both tests, 
A2ARs antagonists prolong escape-directed behavior. Additionally, potential role as 
antidepressants was also observed in attenuated behavioral despairs displayed in 
both tests [55]. The relation between adenosine and depression in preclinical models 
was obtained from the genetic manipulation model of A2AR. Genetic depletion 
of A2ARs resulted in antidepressant-like phenotype in animal models [55]. The 
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A2ARs blockade also relieves stress-induced early hippocampal modifications [56]. 
However, the effect of adenosine neuromodulation system in depression is complex, 
as it has the ability to modulate several other neurotransmission systems [35].
As addressed in previous paragraphs, A2AR emerges as potential target candidate 
in various disorders. This is majorly caused by its unique interaction with D2 recep-
tors, a major psychoactive drug target. Important roles of A2AR were also observed 
in its robust neuroprotective activity, in which it mainly acts in the normalization 
of glutaminergic synapses, the control of mitochondria-induced apoptosis, and the 
control of neuroinflammation [35].
4. Current sources of the adenosine A2A antagonist
The treatment of PD currently focuses on symptom management with dopa-
minergic therapy, such as dopamine precursor L-3,4-dihydroxyphenylalanine 
(L-DOPA) (in combination with peripheral decarboxylase inhibitors) and dopa-
mine agonists [57]. Although L-DOPA is beneficial in patients with PD, with time, 
the span of the effect is shortened), the response becomes less probable, and invol-
untary muscle movements or, in a severe situation, dystonia can emerge [57]. These 
problems highlight the urgent medical need for an alternative mode of therapeutic 
intervention that can relieve the symptoms of the disorder while also allowing a 
decrease in the occurrence of side effects.
Among the non-dopaminergic therapies investigated for the treatment of PD, the 
adenosine A2A receptor antagonists show very convincingly for two main reasons: 
their selective and restricted localization in the basal ganglia circuitry and their 
interaction with dopaminergic receptors. In another word, inhibition of the interac-
tion of adenosine with the A2A receptor may provide a potential treatment for PD.
Figure 3. 
Adenosine A2A inhibitors.
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Many highly selective A2A antagonists, both xanthine and non-xanthine deriva-
tives, have been created, and some of them are being investigated as treatment for 
subjects with PD in various stage of clinical trials (Figure 3) [7, 19, 58–61]. Caffeine 
as a xanthine derivate is developed as a lead compound for the design of antagonist 
of adenosine A2A receptor [62]. Experimental model using 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism is known to be an 
evidence that caffeine have a protective effect in Parkinson’s disease [36, 63]. Some 
A2A antagonists have progressed to clinical trials by various pharmaceutical com-
panies including istradefylline [59], PBS-509, ST1535 and its metabolite ST4206, 
tozadenant, V81444, preladenant, and vipadenant [64]. Several studies of novel 
series of 2-aminoimidazo[4,5-b]pyridine-derivatives [65], arylindenopyrimidine 
[66], and bicyclic aminoquinazoline derivatives [67] as adenosine A2A antagonists 
are reported.
Various computational methods were used to study neuroprotective effect from 
adenosine A2A antagonists such as pharmacophore model [68], QSAR, molecular 
docking [69–71], and molecular dynamics [72, 73]. Orally bioavailable adenosine 
A2A receptor antagonists have been studied for its QSAR and pharmacokinetics 
properties [74].
The study of structure-kinetics relationship (SKR) is done as a complement 
to a SAR analysis at the adenosine A2A receptor. The series of 24 triazolotriazine 
derivatives showing a similar binding kinetics to the putative antagonist ZM241385 
(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)
ethyl)phenol) revealed minor affinity changes, although they varied substantially 
in their dissociation rates from the receptor [75].
5. Future direction of drug discovery of Parkinson’s disease
Various studies have been conducted in the discovery of Parkinson’s drugs 
against the target A2A receptors. The discovery of drugs assisted by computers has 
accelerated in obtaining lead compounds. Apparently, this method takes a lot of 
consideration before entering the preclinical and clinical phases. It is because this 
computational method is more able to describe the answer in preparing the next 
design. This method can also make various predictions of activities that are dif-
ficult to do in the absence of chemical compounds before they are synthesized. In 
silico prediction of various pharmacokinetic parameters and toxicity can also be 
done faster. All of these things can provide a better picture of getting a cure for 
Parkinson’s disease.
6. Conclusions
A2A receptors emerge as potential target candidate in various disorders, caused 
by its unique interaction with D2 receptors, a major psychoactive drug target. 
Various studies have been conducted in the discovery of Parkinson’s drugs against 
the target A2A receptors. In silico study brings a new approach of study with A2A 
receptors.
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